期刊文献+

基质金属蛋白酶及其抑制物在膀胱癌中的表达及意义 被引量:1

The Expression and Clinical Significance of Metalloproteinases and Tissue Inhibitor of Metalloproteinase in Transitional Cell Carcinoma of Bladder
暂未订购
导出
摘要 目的 :探讨MMP2 ,MMP9及TIMP1在膀胱癌中的表达及意义。方法 :采用免疫组化技术 (SP法 )对 5 1例膀胱癌 ,10例正常膀胱组织的MMP2 ,MMP9和TIMP1进行检测 ,结合临床资料进行分析。结果 :MMP2 ,MMP9和TIMP1的阳性表达分别为 5 1% ,2 5 .5 %和 9.8%。MMP2和MMP9在高分级、高分期膀胱癌中表达的阳性率较低分级、低分期膀胱癌高 (P <0 .0 5 )。TIMP1在高分级、高分期膀胱癌中表达的阳性率较低分级、低分期膀胱癌低 (P <0 .0 5 )。MMP2和MMP9阳性表达率高 ,TIMP1阳性表达率低的膀胱癌患者恶性程度增加 ,更具有浸润和转移倾向。随访 4 5例中死亡病例MMP2和MMP9的阳性表达明显高于存活病例 ,二者比较有显著性意义 (P <0 .0 5 )。而TIMP1在死亡及存活病例中的阳性表达比较差异无显著性意义 (P >0 .0 5 )。说明MMP2和MMP9阳性表达与膀胱癌的预后呈正相关。结论 :MMP2 ,MMP9和TIMP1参与膀胱癌的浸润和转移 。 Objective: Our aim was to study expression of MMP2, MMP9, and TIMP1 in transitional cell carcinoma of bladder ( TCCB ). Methods: Fifty one specimens of TCCB and 10 normal specimens as control were assessed by immunohistochemical method ( SP method ). Results: The positive expressions of MMP2, MMP9 and TIMP1 in TCCB were 51% , 25.5%, and 9.8% respectively. The expressions of MMP2 and MMP9 in G 2 to G 3 and T 2 to T 4 stages were significantly higher than those in G 1 and T 1 stages (P<0.05 ). The expression of TIMP1 in G 2 to G 3 and T 2 to T 4 stages were significantly lower than those in G 1 and T 1 stages (P<0.05 ). The expressions of MMP2 and MMP9 tended to increase, with the tumor grade and stage and the expression of TIMP1 tended to decrease. The expressions of MMP2 and MMP9 in those cases who died were significantly higher than those survived (P<0.05 ), while the expression of TIMP1 did not change significantly. Conclusion: The expressions of MMP2 and MMP9 are useful in the prognosis of TCCB.
出处 《中国医科大学学报》 CAS CSCD 北大核心 2002年第1期49-51,共3页 Journal of China Medical University
关键词 基质金属蛋白酶 基质金属蛋白酶组织抑制物 膀胱癌 bladder neoplasms matrix metalloproteinase tissue inhibitors of matrix metalloproteinase
  • 相关文献

参考文献7

  • 1[1]Chambers A,Matrisian LM,Changing M.Views of the role of matrix metalloproteinases in metastasis [J].J Natl Cancer Inst,1997,89:1260-1270.
  • 2[2]Kuglrt A,Hemmerlein B,Thelen P,et al.Expression of metallopr-oteinase 2 and 9 and their inhibitors in renal cell carcinoma [J].J Urol,1998,160: 1914-1918.
  • 3[3]Furukawa A,Tsuji M,Nishitani M,et al.Role of the matrix metalloproteinase and tissue inhibitors of metalloproteinase faimilles in nonivasive and invasive tumors transplanted in mice with severe combined immunodeficiency [J].Urology,1998,521: 849-853.
  • 4[4]Okazaki I Wada N,Nakano M,et al.Difference in gene expression for matrix metalloproteinase-1 between early and advanced hepatocellular carcinomas [J].Hepatology,1997,25: 580-584.
  • 5[5]Liabakk NB,Talbot I,Smith RA,et al.Matrix metalloproteinase 2 ( MMP-2) and matrix metalloproteinase 9 ( MMP-9) type IVcollagenases in colorectal cancer [J].Cancer Res,1996,56: 190-196.
  • 6[6]Davies B,Waxman J,Wasan H,et al.Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion [J].Cancer Res,1993,84;841-850.
  • 7[7]Gohji K,Fujimoto N,Koiyama T,et al.Evaluation of serum levels of matrix metalloproteinase 2 and 3 as new predictor of recurrence in patients with urothelial carcinoma [J].Cancer,1996,78;2379-2387.

同被引文献9

  • 1黄杰雄 张永海 林莹 等.MMP—2和MMP—9与膀胱癌侵袭、复发的关系[J].肿瘤研究与临床,2001,13(1):22-22.
  • 2Furukawa A, Tsuji M, Nishitani M, et al. Role of the matrix metallo -proteinase and tissue transplanted in mice with severe combined immunodeficiency. Urology, 1997,25:580 - 584.
  • 3Goldverg GJ. Stmngin A, Collier IE, et al. Interaction of 92kDa type Ⅳ collagenase with tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase and activation of proenzyme with stromelysin. J Biol Chem, 1992,267:4583-4591.
  • 4Watanable M, Takhashi Y, Ohta T, et al. Inhibition of metastasis in human gastrie cancer cells transfected with tissue inhibitor of metalloproteinase 1 gene in nude mice. Cancer 1996,77:1676 -1680.
  • 5Chesler L, Golde DW, Bersch N, et al. Metalloproteinase inhibition and erythroid potentiation aew independent activities of tisse inhibitor of metalloproteinase - 1. Blood, 1995,86:4506 - 4515.
  • 6Murray GI, Duncan ME, Arbuckle E, et al. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut, 1998,43:791-797.
  • 7Volper OL, Hopwood D, Newman EL, et al. Combined analysis of p53 and TSP - 1 in nonsmall cell carcinoma. Oncogene. 1997,14:1495.
  • 8Davies B, Wax man J, Waxan H, et al. Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res, 1993,84:841-850.
  • 9许克新,侯树坤,杜志军,白文俊,范丙申.检测金属基质蛋白酶及其抑制物对判断膀胱癌浸润和转移的意义[J].中华泌尿外科杂志,2002,23(4):231-233. 被引量:4

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部